The new Xcelligence RTCA HT instrument from Roche merges the power and flexibility of Xcelligence System technology with high-throughput analyses and workflows for automated screening applications.
The system enables researchers to run one to four 384 well E-Plates independently on up to four RTCA HT Stations, thus reading four 384 well plates in parallel.
The RTCA HT instrument's design allows for integration with automated plate and liquid-handling systems.
The first RTCA HT Instrument was installed in February at the University of Queensland in Brisbane, Australia, in the laboratory of Prof Matt Cooper, Institute of Molecular Bioscience.
The system will mainly be used for GPCR and cytotoxicity assays.
Cooper Working Group has a strong focus on the discovery and exploitation of novel biophysical methods for characterising molecular pathways involved in disease, and for research studies on rapid in-vitro and ex-vivo diagnosis of disease, with an emphasis on viral and bacterial infections.
The group has a major effort on rational design and development of novel antibiotics active against drug-resistant pathogens, and is developing cell-specific 'tags' to deliver drugs to the right target, focusing initially on antibiotics and then extending the approach to anti-cancer drugs.
The Xcelligence System utilises impedance as a readout, enabling label-free, non-invasive and kinetic readout of cellular status in response to a multitude of different treatments and therefore can be used in many different cell biological contexts.
The system provides highly incisive and information-rich data not available with other platforms.
